Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Chief Financial Officer | February 14, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 166,492 |
Reported balance
After 2025-02-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-14 · Grant · Acquired 166,492 · Balance 166,492 F4: The option vests and becomes exercisable to the extent of 83,246 shares on February 14, 2025 with the remaining 83,246 shares vesting in eight nearly-equal quarterly installments beginning on February 14, 2026 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 10,490 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 10,490 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 88,968 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 88,968 F2: The option vests and becomes exercisable to the extent of 44,484 shares on February 17, 2023 with the remaining 44,484 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 263,158 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 263,158 F3: The option vests and becomes exercisable to the extent of 131,579 shares on February 13, 2024 with the remaining 131,579 shares vesting in eight nearly-equal quarterly installments beginning on February 13, 2025 and continuing every three months thereafter until fully vested. |
| Common StockSEC Table I · non-derivative | Direct | 7,994 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,994 |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable to the extent of 44,484 shares on February 17, 2023 with the remaining 44,484 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 131,579 shares on February 13, 2024 with the remaining 131,579 shares vesting in eight nearly-equal quarterly installments beginning on February 13, 2025 and continuing every three months thereafter until fully vested.
F4: The option vests and becomes exercisable to the extent of 83,246 shares on February 14, 2025 with the remaining 83,246 shares vesting in eight nearly-equal quarterly installments beginning on February 14, 2026 and continuing every three months thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 19, 2025 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 166,492 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001021771-25-000040 · form4.xml · derivative · entry 5 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,492 Underlying: Common Stock · 166,492 shares Expires 2035-02-14 F4 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 83,246 shares on February 14, 2025 with the remaining 83,246 shares vesting in eight nearly-equal quarterly installments beginning on February 14, 2026 and continuing every three months thereafter until fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 263,158 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001021771-24-000048 · form4.xml · derivative · entry 4 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,158 Underlying: Common Stock · 263,158 shares Expires 2034-02-13 F3 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 131,579 shares on February 13, 2024 with the remaining 131,579 shares vesting in eight nearly-equal quarterly installments beginning on February 13, 2025 and continuing every three months thereafter until fully vested. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 22:32 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 88,968 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001567619-23-003328 · doc1.xml · derivative · entry 3 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,968 Underlying: Common Stock · 88,968 shares Expires 2033-02-17 F2 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 44,484 shares on February 17, 2023 with the remaining 44,484 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:24 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 10,490 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019195 · doc1.xml · derivative · entry 3 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490 Underlying: Common Stock · 10,490 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:24 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 10,490 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019195 · doc1.xml · derivative · entry 2 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,490 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 21:50 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 194 | $3.61 | $700.34 |
DisclosureSEC source: 0001567619-22-012912 · doc1.xml · nonDerivative · entry 1 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,994 Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 16:22 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $4.56 | $912.00 |
DisclosureSEC source: 0001567619-22-012416 · doc1.xml · nonDerivative · entry 1 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 14:47 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 7,600 | $5.71 | $43,396.00 |
DisclosureSEC source: 0001567619-22-008332 · doc1.xml · nonDerivative · entry 1 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Read SEC document |
| November 04, 2021 Filed Nov 16, 2021 21:24 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 10,490 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-21-020581 · doc1.xml · derivative · entry 1 Kristal Robert Eugene · CIK 0001893955 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490 Underlying: Common Stock · 10,490 shares Expires 2031-11-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.